Semaglutide
GLP-1 receptor agonist with extensive Phase 3 trial data for type 2 diabetes and chronic weight management. Prescription-only in most jurisdictions.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
What the research shows
Strong Phase 3 evidence (STEP 1–8 trials). STEP-1 (n=1,961) showed ~14.9% body-weight reduction at 68 weeks vs ~2.4% placebo. SELECT trial (n=17,604) showed reduced major adverse cardiovascular events in overweight/obese adults without diabetes.
What's still experimental
Long-term effects beyond ~3–4 years of continuous use, optimal dosing for weight maintenance after stopping, and use in lean populations remain active research areas.
Anecdotal / community reports
Off-label dosing patterns, microdosing, and stacking with other GLP-1 analogs are widely discussed online but lack RCT support.
Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.
Live research
Updated hourly · sourced from PubMed + ClinicalTrials.govClinical trials (ClinicalTrials.gov)
- GLP1 Fasting Status and Gastric Retention Using Gastric UltrasoundRECRUITINGNCT07251803 · N/A · n=150 · 2026-02-03
- Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation TherapyRECRUITINGNCT06908694 · PHASE4 · n=20 · 2025-07-02
- A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney FunctionCOMPLETEDNCT05015894 · PHASE1 · n=42 · 2021-08-30
- Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in PsoriasisRECRUITINGNCT07401992 · PHASE4 · n=62 · 2026-01-15
Known risks
Pancreatitis risk, gallbladder events, contraindicated in personal/family history of medullary thyroid carcinoma.
Reported side effects
Nausea, GI upset, constipation, fatigue. Discuss with a licensed prescriber.
What requires medical supervision
Prescription medication. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2. Pancreatitis and gallbladder events are documented risks. Requires baseline and follow-up clinical assessment.
Questions for your clinician
- Am I a candidate based on BMI, comorbidities, and contraindications?
- What labs should we monitor (lipase, HbA1c, thyroid function)?
- What's the plan if GI side effects become severe?
- How do we approach maintenance after target weight is reached?
Editorially curated references
Discussions about Semaglutide
- 38Fat Loss·5/7/2026· 0Semaglutide: what STEP-1 actually showed (plain English)
STEP-1 (NEJM 2021, ~2,000 participants, 68 weeks) found semaglutide 2.4mg/week produced ~14.9% body-weight reduction vs ~2.4% placebo. Side effects: GI (nausea, diarrhea) most common, usually subsiding after dose escalation. What it didn't measure well: long-term metabolic adaptation after stopping. Anyone here on it long-term?
- 31Research Studies·5/7/2026· 0Questions to bring to your doctor before starting a GLP-1
If you're considering semaglutide or tirzepatide, here are evidence-based questions worth asking: (1) baseline labs you'd recommend? (2) what's our titration plan? (3) when do we re-evaluate? (4) plan if I stop — managed taper vs cold turkey? (5) interactions with my current meds?